Wilex Ag

Other

Roche Diagnostics Gmbh

Pentapharm Ag

Jörg Stürzebecher

Luis Moroder

Stefan Sperl

Olaf G Wilhelm

Viktor Magdolen

Helmut Vieweg

Peter Wikstroem

Peter Wikström

Peter Hellstern

Uta Stürzebecher, Legal Representative

The present invention relates to a method for the anticoagulation of human blood ex vivo in which blood calcium concentration remains the same, no thrombin is formed and thrombocyte function is not affected. The invention further relates to a blood coagulation factor Xa inhibitor that can be advantageously used in this method, an agent that contains an inhibitor of the blood coagulation factor Xa, and a kit for diagnosing cellular blood components. The anticoagulated blood obtained according to the invention can be used for examining cellular blood components, for example for the diagnosis of thrombocyte function.

Anticoagulation of human blood ex vivo

New urokinase inhibitors having a triisopropylphenylsulfonyl residue as an N&#x3b1;-substituent for 3-amidinophenylalanine are provided. The introduction of the triisopropylphenylsulfonyl residue greatly increases the affinity of the compounds to urokinase and, thereby, increases their inhibitory activity against urokinase. These urokinase inhibitors are useful in determining the role of urokinase and urokinase receptor in various diseases, particularly in tumor propagation and metastasis. Methods of treating tumors and a pharmaceutical composition are also provided.

Urokinase inhibitors

The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.

Selective inhibitors of the urokinase plasminogen activator

The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC 3.4.21.31) of the aryl guanidine type.

The invention relates generally to a novel type of arginine mimetics which are inhibitors of factor X; to pharmaceutical compositions which comprise these mimetics; and to the use of these arginine mimetics for producing compositions for antithrombotic therapy.

[object Object]

Method for determining the catalytic activity of factor IXa

Meta-substituted phenylalanine derivatives

Growing community of inventors

Erfurt-Rhoda, Germany

Jörg Stürzebecher